According to foreign media, Rubius Therapeutics, a newly established biotechnology company, hopes to use red blood cells to replace missing enzymes and eventually to treat some rare and deadly diseases, such as cancer. So far, the company has raised $220m in research and development.

　　Just as doctors use a patient's immune system to improve t-cells to treat cancer, Rubius Therapeutics is using red blood cells to develop targeted disease therapies. Chief executive of the media reported that Rubius Therapeutics thor, strait neeson (Torben Straight Nissen) believe that their therapy is basically a "super blood", because the treatment is the use of red blood cells, rather than chemicals or synthetic materials.

　　Rubius Therapeutics plans to use medical proteins to equip red blood cells and adjust them according to specific conditions. These special red blood cells are then injected into the patient's body and begin to treat the patient's disease. In the end, the super-blood makes up less than 1% of the blood.

　　Initially, the company hopes to develop super blood therapy, so as to replace those with rare diseases patients lack of enzymes in the body, as well as cancer and autoimmune diseases, such as lupus and type 1 diabetes. But unlike T cell therapy, erythrocyte therapy has universal applicability. Rubius Therapeutics website said, we only need a universal donor (with type O blood donors), they can produce enough therapeutic doses, is used in the treatment of hundreds or thousands of different patients.

　　The company is moving toward its goal of raising $100 million recently. In June 2017, the company received $120 million from investors.

　　Nissen said in a research note that the increase of capital to further consolidate the company basis, enable us to speed up the first batch of red blood cell therapy (RCT) product development, the target of the products is enzyme defect treatment, cancer and autoimmune diseases. We have assembled a team of investors, leaders and consultants who provide novel cell therapy for patients with long-term planning and design.

　　It will probably take a while for Rubius Therapeutics to get a wide range of treatments, after all, it's just a concept. First, these therapies must be developed and then validated through a series of clinical trials. If all goes well, superblood will eventually be approved by the food and drug administration (FDA), just like the T cell therapy in 2017.